Structural modeling of V299L and E459K Bcr-Abl mutation, and sequential therapy of tyrosine kinase inhibitors for the compound mutations

✍ Scribed by Dongho Kim; Dong-Wook Kim; Byung-Sik Cho; Hyun-Gyung Goh; Soo-Hyun Kim; Wan-Seok Kim; Jeong Lee; Il-Young Kweon; Sa-Hee Park; Jeong Hyeok Yoon; Nam Doo Kim; Haarin Chun

• Publisher: Elsevier Science
• Year: 2009
• Tongue: English
• Weight: 592 KB
• Volume: 33
• Category: Article
• ISSN: 0145-2126
• DOI: 10.1016/j.leukres.2008.12.017

✦ Synopsis

Sequential treatment with different tyrosine kinase inhibitors (TKIs) is one of the strategies for handling chronic myeloid leukemia (CML) in which dynamic change in Bcr-Abl kinase domain mutation is often an obstacle faced during TKI therapy. Here we report successful sequential therapy with different TKIs for the CML patient harboring V299L and E459K compound mutations. Molecular monitoring including quantitative analysis of BCR-ABL transcript level and mutation analysis were performed regularly for successful treatment. Additionally a drug-target complex was structurally modeled to investigate influence of amino acid substitutions on drug resistance, and to choose alternative TKI in sequential therapy, suggesting protein structural modeling can be useful approach in selecting alternative TKIs.